Prior authorization of newer insomnia medications in managed care: is it cost saving?
OBJECTIVE
New pharmacotherapeutic treatment options are available to treat patients with 1 or more insomnia symptoms. However, these new pharmaceuticals are subject to a variety of managed-care tools, such as prior authorizations, that may restrict access to these medications. The objective of this study was to evaluate the economic consequences to a health plan that requires prior authorization for nonbenzodiazepine medications approved for the treatment of insomnia characterized by difficulties both falling and staying asleep.


METHODS
An economic model was constructed to determine the effects of a typical prior-authorization program across a hypothetical managed-care population. Model parameters were derived from national estimates and a literature review.


RESULTS
Economic consequences of a prior-authorization program were based on a hypothetical managed-care plan with 500,000 insured patients. An estimated acquisition cost of $300 per 100 tablets of medication requiring prior authorization, $40 to process each priorauthorization request, and prior-authorization rejection rates of 2% to 5% were considered. Using the default-model inputs of the hypothetical plan characteristics and costs, the economic model estimated a loss of $600,000 to $700,000 per year to the health plan. In a 3-way threshold sensitivity analysis when prior-authorization rejection rate was increased to 5%, the cost of each request in the prior-authorization program was decreased to $20, and the cost of a first-generation nonbenzodiazepine was decreased to a generic price (i.e. $100 per prescription), the model continued to show a net loss to managed care in each case.


CONCLUSIONS
This model showed that requiring prior authorization for newer sleep treatments might not be a cost-saving strategy for managed-care organizations.
Balkrishnan
Rajesh
R
College of Pharmacy, Ohio State University, Columbus, OH 43210, USA. balkrishnan.1@osu.edu
Joish
Vijay N
VN
Bhosle
Monali J
MJ
Rasu
Rafia S
RS
Nahata
Milap C
MC
D003362:Cost-Benefit Analysis / Q000379:methods; D016527:Drug Costs / Q000706:statistics & numerical data; D011307:Drug Prescriptions / Q000191:economics* / Q000706:statistics & numerical data; D005569:Formularies as Topic; D006297:Health Services Accessibility / Q000191:economics; D006801:Humans; D006993:Hypnotics and Sedatives / Q000191:economics* / Q000627:therapeutic use*; D007345:Insurance Claim Review; D008329:Managed Care Programs / Q000191:economics* / Q000458:organization & administration; D017059:Models, Econometric; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy* / Q000191:economics*; D014481:United States
D006993:Hypnotics and Sedatives
South Med J. 2001 Sep;94(9):866-73
11592743
Clin Ther. 2005 Dec;27(12):1970-9
16507384
Hum Psychopharmacol. 2004 Jul;19(5):305-22
15252823
Addiction. 2003 Oct;98(10):1371-8
14519173
N Engl J Med. 2004 Nov 18;351(21):2187-94
15548779
Sleep. 1994 Sep;17(6):551-4
7809569
Am J Manag Care. 1998 Jan;4(1):79-86
10179908
J Manag Care Pharm. 2005 May;11(4):358-61
15871651
Ann Clin Psychiatry. 2006 Jan-Mar;18(1):49-56
16517453
Am J Psychiatry. 1997 Oct;154(10):1417-23
9326825
Clin Ther. 2003 Jan;25(1):250-72
12637125
J Clin Psychiatry. 2005;66 Suppl 9:18-23; quiz 42-3
16336038
Sleep. 2005 Jun;28(6):715-9
16477958
Mich Law Rev. 2002 Nov;101(2):602-47
12632592
Expert Rev Pharmacoecon Outcomes Res. 2004 Apr;4(2):165-9
19807520
Prim Care. 2005 Jun;32(2):375-88
15935191
J Manag Care Pharm. 2003 Jul-Aug;9(4):327-34
14613451
Health Aff (Millwood). 2000 Mar-Apr;19(2):240-7
10718038
Health Aff (Millwood). 2006 Jan-Feb;25(1):186-96
16403753
Sleep Med Rev. 2004 Feb;8(1):63-72
15062211
Health Aff (Millwood). 2005 May-Jun;24(3):780-9
15886173
CNS Drugs. 2004;18(5):297-328
15089115
J Manag Care Pharm. 2003 Jan-Feb;9(1):36-44
14613360